Intranasal anthrax vaccine approved to advance into a pre-clinical toxicology study
by Press Release from Outbreak News Today on (#2TD31)
NanoBio Corporation today announced the progression of a novel intranasal anthrax vaccine into a pre-clinical IND-enabling toxicology study funded by the U.S. National Institute of Health's National Institute of Allergy and Infectious Diseases (NIAID). The vaccine combines NanoBio's novel intranasal nanoemulsion (NE) adjuvant with recombinant protective antigen (rPA) for anthrax from Porton Biopharma Ltd (PBL). ["]
The post Intranasal anthrax vaccine approved to advance into a pre-clinical toxicology study appeared first on Outbreak News Today.